000			03614nam a2200397 i 4500
999			_c395872 _d395872
001			395872
003			ES-MaUEC
005			20230118120105.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			211216s2022 sz a o |||| 0|eng d
020			_a9783030844325
024	7		_a10.1007/978-3-030-84432-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC268.5 _b2022 EB
245	0	0	_aBiomarkers in Carcinoma of Unknown Primary _cedited by Sulen Sarioglu, Ozgul Sagol, Anil Aysal
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (X, 473 páginas) _b144 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aChapter 1) Definition of "Tissue-based Biomarker", Its Place in Medicine and Molecular Pathology -- Chapter 2) The Concept and Mechanisms of Metastasis -- Chapter 3) Biomarkers in Skin Carcinomas -- Chapter 4) Biomarkers in Head and Neck Carcinomas -- Chapter 5) Biomarkers in Pulmonary Carcinomas -- Chapter 6) Biomarkers in Endocrine Organ Carcinomas -- Chapter 7) Biomarkers in Gastrointestinal System Carcinomas -- Chapter 8) Biomarkers in Hepatopancreatobiliary Carcinomas -- Chapter 9) Biomarkers in Urinary Tract and Male Genital System Carcinomas -- Chapter 10) Biomarkers in Gynecological Carcinomas -- Chapter 11) Biomarkers in Breast Carcinomas -- Chapter 12) Diagnostic Approach According to More Frequent Metastatic Sites-Liver, Lungs, Bone, Lymph Nodes -- Chapter 13) Diagnostic Approach According to Uncovered Metastatic Sites - Mediastinum-Timus, Peritoneum, Central Nervous System, Soft Tissue -- Chapter 14) Management of the Patients with Primary Unknown Carcinoma and the Role of Biomarkers -- Chapter 15) Treatment Approach to Carcinomas of Unknown Primary -- Appendix.
520			_aThis book aims to examine all immunohistochemical and molecular pathological biomarkers that can be useful and effective in patient diagnosis, prognosis and treatment decision, especially when faced with a carcinoma of unknown primary. For this purpose, epithelial malignancies of all systems and related biomarkers are examined one by one, and to look at the subject through the metastatic regions window, biomarkers that can be used to determine the primary focus for carcinomas seen in the areas most frequently metastasized are emphasized. With this bi-directional perspective, the reader is able to find biomarkers of any type of carcinoma on a system basis, as well as access to which biomarkers can be used when faced with a metastatic carcinoma. The importance of biomarkers in patient follow-up and treatment is also conveyed through the clinician's eye, and so biomarkers are handled with a holistic approach in all aspects. This book primarily targets pathologists, as well as clinicians (oncologists and surgeons) who manage cancer patients.
988			_aSpringer_Medicine_2022
650		7	_2embne _9146492 _aCarcinogénesis
776	0	8	_iPrinted edition: _z9783030844318
776	0	8	_iPrinted edition: _z9783030844332
776	0	8	_iPrinted edition: _z9783030844349
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-84432-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2023 _dz _eb _zSI